{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-279724","form_type":"8-K","ticker":"SPRO","cik":"0001701108","company_name":"Spero Therapeutics, Inc.","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.752510+00:00","generated_at":"2026-06-22T04:00:23.470126+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Spero Therapeutics closes exclusive license agreement with GSK for tebipenem HBr","bullets":["Received $66 million upfront payment from GSK under the exclusive license agreement.","GSK affiliate purchased 7,450,000 shares of Spero common stock for approximately $9 million.","Spero eligible for up to $525 million in development, sales, and commercial milestones plus tiered royalties.","Spero will conduct a follow-up Phase 3 trial; GSK responsible for further development and commercialization outside Meiji Seika territories.","GSK granted exclusive license to develop and commercialize tebipenem HBr in all territories except Japan and certain Asian countries."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-279724","json":"https://secwatch.observer/filing/0001193125-22-279724.json","markdown":"https://secwatch.observer/filing/0001193125-22-279724.md","text":"https://secwatch.observer/filing/0001193125-22-279724.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701108/000119312522279724/0001193125-22-279724-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701108/000119312522279724/d416179d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T04:00:23.470126+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}